Home » FDA Rejects Watson Bioequivalency Claims to Block Generic
FDA Rejects Watson Bioequivalency Claims to Block Generic
The FDA has categorically turned down Watson Pharmaceuticals’ attempt to block Sandoz from producing a generic version of its prostate drug Rapaflo. The Actavis subsidiary filed a citizen petition earlier this year asking the FDA to throw out a Paragraph IV ANDA submission by Sandoz for a Rapaflo (silodosin) copycat, claiming its bioequivalency requirements were not sufficiently stringent, which could result in patients being over-dosed or under-dosed.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May